FDA Approves Pegfilgrastim Biosimilar

November 5, 2018 – The FDA has granted an approval to pegfilgrastim-cbqv (CHS-1701), a pegfilgrastim biosimilar, for patients with cancer receiving myelosuppressive chemotherapy, according to Coherus BioSciences, Inc, the manufacturer of the agent. The biosimilar was also granted approval by the European Commission for the same indication on September 21, 2018. “We are excited to announce that Coherus has received FDA approval for pegfilgrastim-cbqv … (leggi tutto)